Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study

INTRODUCTION: Nocturnal hypertension is clinically important for patients with type 2 diabetes (T2D), considering its strong correlation with cardiovascular events. We aim to test the hypothesis that the sodium-glucose cotransporter 2 inhibitor, luseogliflozin, ameliorates nocturnal hypertension mor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Kameda, Reina, Nomoto, Hiroshi, Cho, Kyu Yong, Kawata, Shinichiro, Omori, Kazuno, Takeuchi, Jun, Nagai, So, Kurihara, Yoshio, Aoki, Shin, Nakamura, Akinobu, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Diabetes and Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044823/
https://ncbi.nlm.nih.gov/pubmed/32034028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-034883
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados